What happened with IPSC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Century Therapeutics is a biotechnology company developing cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. It genetically edits stem cells and turns them into insulin-producing islet cells or immune cells intended for use across patients. Its Allo-Evasion technology is designed to reduce patients’ immune rejection of these cells; that intended benefit is still being tested.
Its main development priorities are CNTY-813 for type 1 diabetes and CNTY-308 for B-cell-mediated diseases. Both are undergoing studies needed before seeking permission to test them in humans and have not entered human trials. CNTY-101 remains in clinical development through the investigator-sponsored CARAMEL trial. The company relies on technology licensed from FUJIFILM Cellular Dynamics to reprogram cells and produce immune cells.
Bristol-Myers Squibb supplied the company’s revenue to date through a collaboration to develop engineered immune-cell therapies for blood cancers. That agreement has ended and will provide no further revenue. Century has no approved products or product-sales revenue and depends on additional capital to fund development. It expects prospective collaborations to be its main revenue source before product sales. Selling therapies would first require successful development, regulatory marketing approval and manufacturing capacity.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Century Therapeutics’ prospects hinge on clinical success in diabetes and autoimmune cell therapies, with FUJIFILM Cellular Dynamics supplying important licensed technology and some CNTY-101 clinical manufacturing.
Fate Therapeutics competes with Century in making ready-to-use T-cell and natural-killer-cell therapies for cancer and immune disorders from engineered induced pluripotent stem cell (iPSC) master banks. Its progress tests a similar production approach; Ono pays Fate to research and develop solid-tumor candidates.
Sana Biotechnology’s progress in replacing cells to treat type 1 diabetes is a direct competitive benchmark for Century’s CNTY-813. Both are developing cell therapies for these patients, and Sana has not generated revenue from product sales or any other source.
Nkarta competes with Century to treat B-cell-mediated autoimmune diseases using engineered natural killer cells prepared for off-the-shelf use. Watch its NKX019 clinical progress as a comparison for Century’s CNTY-101; Nkarta had no product-sales revenue through December 31, 2025.
CRISPR Therapeutics competes with Century across type 1 diabetes cell replacement and engineered immune-cell treatments for autoimmune disease and cancer. Its beta-cell replacement and CAR-T candidates are the relevant programs to watch, rather than the diabetes gene-editing technology it licenses to Vertex for payments and potential royalties.
Artiva Biotherapeutics’ AlloNK competes with Century’s CNTY-101 in treating autoimmune disease with donor-derived natural killer cells. AlloNK development and manufacturing progress offer a comparison for Century’s approach; Artiva had no product-sales revenue through December 31, 2025.
Adicet Bio challenges Century in off-the-shelf immune-cell treatments for autoimmune disease and cancer, but uses donor-derived gamma delta T cells rather than Century’s iPSC-derived cells. Its lead autoimmune candidate prula-cel provides a concrete comparison for Century’s autoimmune programs.
Vertex Pharmaceuticals’ type 1 diabetes cell-therapy progress is a competitive benchmark for Century’s beta-islet program CNTY-813. Vertex also sells medicines to specialty pharmacies, distributors and wholesalers, but its diabetes development—not those existing sales—is the tie to watch here.
Cabaletta Bio competes with Century to treat B-cell-mediated autoimmune diseases using engineered immune cells, with Cabaletta developing T-cell therapies. Its clinical and preclinical development is the relevant comparison: it has not generated product-sales revenue and needs successful development and approval before it can do so.
Kyverna Therapeutics offers a competing autoimmune cell-therapy approach to Century’s iPSC-derived immune cells by developing engineered T-cell treatments. Watch KYV-102’s whole-blood manufacturing approach, which is intended to avoid apheresis collection and shorten production time; those improvements remain intended, not established.
Allogene Therapeutics competes with Century in engineered T-cell treatments prepared for off-the-shelf use against cancer and autoimmune diseases. Allogene uses donor-derived cells, and through December 31, 2025 its revenue came exclusively from licensing to Overland Therapeutics, not treatment sales.
Cartesian Therapeutics competes with Century in autoimmune disease by making engineered T-cell therapies from each patient’s own cells rather than off-the-shelf immune cells. Its Descartes-08 progress offers a contrasting treatment model: cells are made for one patient and returned for six weekly infusions.
Caribou Biosciences competes with Century in off-the-shelf engineered immune-cell therapies, with overlapping opportunities in B-cell cancers. Its vispa-cel phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma is a concrete cancer-development benchmark, rather than a comparison for Century’s diabetes program.
Sana Biotechnology, Inc. earningsSANA
Sana Biotechnology’s report will show how its type 1 diabetes cell-replacement program is progressing, a read-through on the treatment path Century Therapeutics is pursuing with CNTY-813.
Watch the program’s stated stage and progress, not Sana’s revenue or loss as evidence of treatment efficacy. Continued advancement would show that cell replacement is moving toward clinical testing; delays or obstacles would underscore the development challenges, without deciding CNTY-813’s outcome.
Cabaletta Bio, Inc. earningsCABA
Cabaletta Bio’s report will show how its engineered T-cell programs for B-cell-mediated autoimmune diseases are progressing, a comparison for the development path of Century Therapeutics’ CNTY-308.
Watch Cabaletta’s reported clinical and preclinical progress. Advancement would show engineered cell therapies continuing through development for this patient group; stalled or troubled programs would show that hurdles remain and that Century’s CNTY-308 has not thereby cleared them.
Century Therapeutics, Inc. earningsThis company
Century Therapeutics no longer has BMS collaboration revenue and has no products for sale, so its report will show whether spending is advancing CNTY-813 and CNTY-308 while preserving its funding runway.
Read research and development expense and general and administrative expense alongside progress on the two programs. Controlled costs with continued progress would support development within the current funding plan; rising costs with limited progress would mean faster cash use and potentially earlier financing.
Fate Therapeutics, Inc. earningsFATE
Fate Therapeutics’ report will show how its iPSC-cell-bank therapies are progressing, a read-through on the production approach underlying Century Therapeutics’ pipeline.
Watch Fate’s program progress and whether production of its ready-to-use therapies encounters obstacles. Advancement with smooth production would add evidence that this iPSC approach can support drug development; setbacks would highlight platform and manufacturing risks Century also faces, though the products and processes are not identical.
